Table 1. Baseline clinical and biochemical characteristics by prescription group.
| Characteristic | Group A | Group B | Group C | Total | P value |
|---|---|---|---|---|---|
| Number | 0504 | 2,316 | 81 | 2,901 | |
| Male sex | 284 (56.4) | 1,245 (53.8) | 32 (39.5) | 1,561 (53.8) | 0.020 |
| Age, yr | 58.3±10.8 | 58.8±10.9 | 59.4±11.3 | 58.8±10.9 | 0.508 |
| Body weight, kg | 68.1±11.2a | 65.4±10.6b | 60.2±12.2c | 65.7±10.8 | <0.001 |
| BMI, kg/m2 | 25.4±3.1a | 24.3±3.0b | 23.4±3.9c | 24.4±3.0 | <0.001 |
| Diabetes duration, yr | 7.3±5.1a | 7.9±5.5a | 9.7±5.5b | 7.8±5.5 | 0.005 |
| HbA1c, % | 8.4±1.1a | 9.1±1.4b | 10.3±2.3c | 9.0±1.4 | <0.001 |
| FPG, mg/dL | 178±61a | 200±61b | 193±74a,b | 196±61 | <0.001 |
| Metformin dose, mg | 1,242±521a | 1,234±513a | 1,078±489b | 1,231±514 | 0.024 |
| Sulfonyluread | |||||
| Glimepiride | 370 (73.3) | 2,093 (90.2) | 75 (91.5) | 2,538 (87.3) | <0.001 |
| Gliclazide | 104 (20.6) | 150 (6.5) | 3 (3.7) | 257 (8.8) | <0.001 |
| Glibenclamide | 31 (6.1) | 78 (3.4) | 4 (4.9) | 113 (3.9) | 0.014 |
Values are presented as number (%) or mean±standard deviation. P values were calculated using chi-square test and analysis of variance.
BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose.
a,b,cThe data with different superscript letters represent significant difference according to Scheffe's post hoc test, dSome patients were taking more than two types of sulfonylurea.